Search the webpage

Category: Glaucoma

Experimentica Ltd. offers a validated human trabecular meshwork cells for a variety of custom in vitro projects targeted at the trabecular meshwork.

SUMMARY

Species

Human

In vitro insult

TBD

Format

96-well plate

Read-outs

Custom, e.g. actin fiber length, focal adhesions

Please contact us, if you would like to receive more information: info@experimentica.com

IMAGES

Representative examples from primary human trabecular meshwork  cells

Effect of the rho kinase inhibitor netarsudil on actin fiber arrangement in primary human trabecular meshwork cells. Netarsudil (1.2 µM) results in a significant reduction of actin fiber length as assessed by labeling with fluorescently-labelled phalloidin (Actin GreenTM 488 ReadyProbesTM, Thermo Fisher).

Effect of the rho kinase inhibitor netarsudil on focal adhesions in primary human trabecular meshwork cells. Netarsudil (1.2 µM) results in a significant reduction in the number of focal adhesions, as quantified using anti-paxillin antibody (clone 5H11, EMD Millipore).

SELECTED PUBLICATIONS

REFERENCES

  • Lin, C.-W. W. et al. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. J Ocul Pharmacol Ther 34, 40–51 (2018).

LATEST NEWS

Refinement of the EAE Mouse Model

Experimental Autoimmune Encephalomyelitis (EAE) is used to study Multiple Sclerosis (MS) a chronic neuroinflammatory demyelinating disorder of the CNS. EAE ... Read More

Novel model for corneal permeability in vitro testing through the combined use of collagen-based hydrogels with stratified corneal epithelial cells

The cornea is critical for penetration of topically applied drugs into the eye. Assessment of the permeability properties of drug ... Read More

A synthetic metalloporphyrin SOD mimetic protects corneal epithelial cells from oxidative stress-induced damage in vitro and in vivo

Keratoconjunctivitis sicca (KCS) is a multifactorial disease of the lacrimal glands and ocular surface1. Pathological findings in patients with KCS ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!